Goldbach-Mansky R, King P D, Taylor A P, Dupont B
Laboratory of Human Immunogenetics, Sloan-Kettering Institute for Cancer Research, New York, NY 10021.
Int Immunol. 1992 Dec;4(12):1351-60. doi: 10.1093/intimm/4.12.1351.
In this study we investigated the differential effect of the co-stimulatory receptor ligand molecules CD2/LFA-3, LFA-1/ICAM-1, and CD28/B7 on microbial superantigen mediated activation of CD4+ T cells. Highly purified CD4+ T cells, depleted of antigen presenting cells (APCs), do not proliferate in response to the superantigen, staphylococcal enterotoxin B (SEB). However, CD4+ T cells do respond to SEB in the presence of the LFA-3, ICAM-1, and B7 positive erythroleukemic cell line K562, murine L cells, human B7 transfected L cells or CD28 mAb. The K562 plus SEB induced response can be inhibited by combinations of mAbs to CD2 and LFA-1, and to LFA-3, ICAM-1, and B7. Addition of CD28 mAb to the CD2 and LFA-1 inhibited cultures could restore the response. Furthermore, soluble CD28 mAb alone is able to synergize with SEB to induce a proliferative CD4+ T cell response. CD4+ T cells depleted of APCs could also be activated by a pool of four mAbs directed to the V beta 5, V beta 6, V beta 8, and V beta 12 region of the TCR when a co-stimulatory signal was provided by the CD28 mAb, while the V beta mAbs alone or in combination are unable to activate CD4+ T cells in the absence of APCs. In contrast, addition of soluble mAbs to CD2 and LFA-1 molecules failed to co-stimulate SEB activated CD4+ T lymphocytes. The kinetics of the different modes of activation are distinct. SEB induced proliferation is most efficient in the presence of autologous APCs with maximal proliferation at a log4 lower SEB concentration than when CD28 mAbs were used. SEB plus K562 activation peaks on day 7, while SEB plus CD28 mAb induced proliferative responses do not peak until day 9. Thus, superantigen mediated activation of CD4+ T cells requires co-stimulatory signals, among which CD28 has distinct and unique effects.
在本研究中,我们调查了共刺激受体配体分子CD2/LFA-3、LFA-1/ICAM-1和CD28/B7对微生物超抗原介导的CD4+T细胞活化的不同作用。高度纯化的、不含抗原呈递细胞(APC)的CD4+T细胞,对超抗原葡萄球菌肠毒素B(SEB)无增殖反应。然而,在LFA-3、ICAM-1和B7阳性的红白血病细胞系K562、鼠L细胞、人B7转染的L细胞或CD28单克隆抗体存在的情况下,CD4+T细胞对SEB有反应。K562加SEB诱导的反应可被针对CD2和LFA-1以及针对LFA-3、ICAM-1和B7的单克隆抗体组合所抑制。向CD2和LFA-1抑制的培养物中添加CD28单克隆抗体可恢复反应。此外,单独的可溶性CD28单克隆抗体能够与SEB协同诱导增殖性CD4+T细胞反应。当由CD28单克隆抗体提供共刺激信号时,针对TCR的Vβ5、Vβ6、Vβ8和Vβ12区域的四种单克隆抗体组成的混合物也能够激活不含APC的CD4+T细胞,而单独或联合使用Vβ单克隆抗体在无APC的情况下无法激活CD4+T细胞。相反,向CD2和LFA-1分子添加可溶性单克隆抗体未能共刺激SEB激活的CD4+T淋巴细胞。不同激活模式的动力学是不同的。在自体APC存在的情况下,SEB诱导的增殖最有效,与使用CD28单克隆抗体时相比,在低4个对数浓度的SEB时增殖达到最大值。SEB加K562激活在第7天达到峰值,而SEB加CD28单克隆抗体诱导的增殖反应直到第9天才达到峰值。因此,超抗原介导的CD4+T细胞活化需要共刺激信号,其中CD28具有独特的作用。